A subsequent nationwide study in Japan comparing 82 patients who received MOG prior to allo-HCT with 914 patients who did not similarly demonstrated a significantly increased risk of steroid-refractory GVHD in the MOG group. The gene discussed is MOG; the disease is graft versus host disease.